Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X4NF
|
|||
| Former ID |
DIB006451
|
|||
| Drug Name |
Radiosensitizer gene therapy
|
|||
| Synonyms |
Radiosensitizer gene therapy (prostate cancer)
Click to Show/Hide
|
|||
| Indication | Pancreatic cancer [ICD-11: 2C10] | Phase 3 | [1] | |
| Company |
Advantagene
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thymidine kinase 1 (TK1) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Advantagene. | |||
| REF 2 | Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res. 1997 Nov;3(11):2081-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.